T
TheraMe uses microfluidic technology to test over 100 therapy options from tiny cancer biopsies, enabling comprehensive drug screening. Proprietary computational programs and machine learning analyze the data to recommend the most effective personalized treatment within 8‑10 business days. The platform also supports repeat screenings to monitor resistance and identify second‑line options.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- TheraMe uses microfluidic technology to test over 100 therapy options from tiny cancer biopsies, enabling comprehensive drug screening. Proprietary computational programs and machine learning analyze the data to recommend the most effective personalized treatment within 8‑10 business days. The platform also supports repeat screenings to monitor resistance and identify second‑line options.